Editas Medicine, Inc.

EDIT Healthcare Biotechnology

Editas Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 25.4% from fiscal 2024. In the quarter to June 2026, revenue grew 232.3%, EPS grew 76.2% and free cash flow grew 40.7%, each against the same quarter a year earlier.

2.47 0.28 −10.18%
Market cap
$422.3M
P/E
0.0×
Fwd P/E
−2.7×
Dividend yield
—
F-score
2/9
Altman Z
−13.39
Beneish M
−2.46
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
8.22 6.25 4.49 6.74
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(13.07) (10.48) (5.00) (10.14)
P/B ratio
3.67 54.84 6.67 23.24
Price to Tangible BV
3.67 54.84 6.67 23.24
EV/Sales
4.41 3.89 1.67 3.87
EV/EBITDA
0.00 0.00 0.00 0.00
EV/Operating CF
(1.73) (1.07) (0.41) (1.00)
EV/FCF
(1.72) (1.07) (0.41) (0.99)
Quick Ratio
3.13 3.17 3.50 2.81
Current Ratio
3.19 3.22 3.54 2.86
Net Debt/EBITDA
11.58 5.04 21.10 6.93
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.21 0.19 0.15 0.18
Operating CF/Net income
1.62 0.92 6.47 1.23
Capex/Depreciation
(0.39) 0.13 0.07 (0.66)
Interest Coverage
(17.49) (23.32) 16.71 (10.23)
Research and Development Expense of Revenue
169.72% 621.69% 110.76% 262.16%
Selling, General and Administrative Expense of Revenue
97.59% 361.50% 45.89% 163.28%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
18.44% 74.25% 8.61% 29.54%
Graham Net Nets
0.22 (0.07) 0.03 (0.04)
Graham Number
0.00 0.00 0.00 0.00
Earnings Yield
(23.15%) (49.80%) (92.20%) (68.59%)
Free Cash Flow Yield
(31.12%) (58.18%) (91.01%) (57.76%)
Revenue per Share
0.10 0.03 0.28 0.08
Operating CF per Share
(0.25) (0.24) (0.41) (0.34)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.25) (0.23) (0.41) (0.35)
Cash per Share
1.77 1.26 1.65 1.84
Shareholders Equity per Share
0.88 0.05 0.31 0.15
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
0.88 0.05 0.31 0.15
Free Cash Flow
(29.67) (23.00) (36.33) (31.28)
Working Capital
149.63 88.29 117.65 115.12
Capital Expenditures
(0.11) 0.06 0.06 (0.43)
Net Current Asset Value
85.98 (16.86) 4.65 (11.41)
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
0.01 (0.02) 0.00 0.06
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Receivables
1.66 1.55 15.72 4.13
Average Payables
5.73 4.90 4.05 7.83
Average Assets
223.97 206.50 264.06 264.66
Average Common Equity
62.24 33.41 80.78 94.54

Fold the line items

Columns are period end dates